1. New Approved Treatment and Indications in Oncology
Another blood cancer treatment with a novel mechanism of action is Venclexta (venetoclax), which was approved for the treatment of patients more details...


2. Leukemia: Causes, Symptoms, and Treatments.
Leukemia is a type of cancer that affects blood cell formation and the lymphatic system. It can be classified by cell type, lymphoid or myeloid, and the rate of progression, acute or chronic. more details...


3. Top Discoveries in Chronic Lymphocytic Leukemia at ASH 2018
With respect to the treatment of chronic lymphocytic leukemia (CLL), 2018 was notable for an improved understanding of ibrutinib-based therapies. more details...


4. Truxima Becomes First Biosimilar to Rituxan Approved in US for Non-Hodgkin’s Lymphoma
The U.S. Food and Drug Administration has approved Truxima (rituximab-abbs), a biosimilar to Rituxan (rituximab), for three CD20-positive non-Hodgkin’s lymphoma indications, Celltrion and Teva announced. more details...


6. DARZALEX® (daratumumab) Combination Regimens Show Positive Results for Newly Diagnosed and Relapsed Patients with Multiple Myeloma
SAN DIEGO, Dec. 1, 2018 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today long-term results from the Phase 3 ALCYONE study showing that the addition of DARZALEX® (daratumumab) to bortezomib, melphalan and prednisone (VMP) continued to demonstrate significant improvement in progression-free survival (PFS) in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (ASCT).more details...